Suyash Prasad, CMO and Head of R&D at Taysha Gene Therapies, Inc. (TSHA), sold 12,861 shares at $3.51 ($48K) on 2022-07-05, disclosed to the SEC on 2022-07-07.
Scheduled sale ($48k) by CMO and Head of R&D under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $3.51 | 3,905 | $14K | 28.8% |
| 2 | $3.79 | 8,956 | $34K | 71.2% |
| Total | $3.70 avg | 12,861 | $48K | 100% |
| Filing → |
| BOLD | SELL | 2019-05-15 | $738K | — | Filing → |
| BOLD | SELL | 2019-02-27 | $301K | — | Filing → |
| BOLD | SELL | 2018-10-02 | $536K | — | Filing → |